http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0145642-A3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ffd35ce528588b4d14c23342fe7d3668 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7ae95e7759e7ecd9a4ab7f46795c1ce3 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0073 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7056 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7056 |
| filingDate | 2000-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_16c8be3a86d76f9e28dd18f19f277704 |
| publicationDate | 2001-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-0145642-A3 |
| titleOfInvention | Pulmonary delivery of ribavirin or levovirin™ for systemic and quasi-systemic treatment of disease |
| abstract | A method of treating a systemic viral disease in a patient has a first step in which the disease is correlated with an increase in Type 1 cytokine activity and a decrease in Type 2 activity. In a further step, a systemic dosage of a drug is identified that is effective to increase the Type 1 activity and decrease the type 2 activity, wherein the drug is Ribavirin or Levovirin™ and in a still further step, the dosage of the drug is administered to the patient via pulmonary delivery. A further method of treating a viral disease has a first step in which the disease is correlated with an infection of dendritic cells, and the dendritic cells are targeted by administering Ribavirin or Levovirin™ via a pulmonary aerosol. |
| priorityDate | 1999-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 17.